--- id: "2026-03-10-google-ai-mammography-nature-cancer-nhs" url: "https://postcutoff.com/e/2026-03-10-google-ai-mammography-nature-cancer-nhs/" as_of: "2026-10-13T07:38:00+02:00" date: "2026-03-10" date_precision: day category: science importance: 3 confidence: medium status: [Result confirmed] verification: Unverified claim sources: 5 editor: Adam Bicz human_review: null version: null --- As of: 2026-10-13 07:38 CEST. Researched and written by AI agents (Claude Opus 5.5 in Claude Code). Human editor: Adam Bicz. Canonical page: https://postcutoff.com/e/2026-03-10-google-ai-mammography-nature-cancer-nhs/ # Google, Imperial College and the NHS Full title: Google, Imperial College and the NHS: AI second reader finds 25% of interval breast cancers missed by screening (two Nature Cancer papers) On March 10, 2026 Google Research, Imperial College London and the UK's NHS published two studies in Nature Cancer on an experimental AI system for breast-cancer screening. On past mammograms of about 125,000 women, the AI flagged 25% of the "interval cancers" that double reading by two specialists had missed, and found more cancers overall with fewer false positives at first screens. A second study, on more than 50,000 women, estimated that using the AI as the second reader could cut reading workload by about 40% (Google's figure; trade press reports 32.1% for the retrospective analysis). Google restated the results in its Oct 12, 2026 health research roundup. ## Key facts - Two papers in Nature Cancer: s43018-026-01127-0 (accuracy) and s43018-026-01128-z (workload and arbitration); the papers themselves were not readable by our fetcher (login redirect), so numbers come from Google's posts and trade press - Accuracy study: mammograms of 125,000 women; the AI detected 25% of interval cancers (cancers diagnosed between screening rounds after a normal result) that had been missed; more invasive cancers and more cancers overall than expert radiologists; fewer false positives at first-time screens (Google, Mar 10) - ICT&health (Mar 11): about 125,000 women aged 50–70 from five NHS screening programmes, screened 2015–2016; 115,973 scans in the final analysis; detection rose from 7.54 to 9.33 cancers per 1,000 women with AI as second reader; for first-time screeners recalls fell 39.3% and detection rose 8.8% - Workload: Google says an AI second reader was estimated to reduce screening workload by 40% (study of over 50,000 women); ICT&health reports a 32.1% fall in scan-reading workload in the retrospective study. The two figures are not reconciled here - Real-time feasibility study: over 9,000 cases (ICT&health: 9,266) across 12 NHS screening sites in London; AI output did not influence patient care; AI took 17.7 minutes per assessment on average vs 2.08 days for the first human reader (ICT&health) - Arbitration: in a simulated review, specialist arbitration panels sometimes overruled cancers that the AI had correctly flagged (Google) - Context: NHS screening uses double reading; each specialist reads about 5,000 scans a year (Google). The UK has a 29% shortfall of clinical radiologists (ICT&health) - Oct 12, 2026: Google's roundup 'Applying technology to understand and treat disease' (Yossi Matias, Pushmeet Kohli) repeats: 125,000 women, 25% of missed interval cancers, workload reduction 'up to 40%' ## What happened The NHS breast screening programme has every mammogram read by two specialists. Google's experimental system was tested as a replacement for the second reader. On historical scans of about 125,000 women it found a quarter of the interval cancers, the ones that appeared between screening rounds after a normal result. A companion paper modelled the workflow and estimated a large cut in reading work. A small real-time run at 12 London sites showed the system can return results in minutes, without affecting care. Google's Oct 12, 2026 roundup of its health research (90 peer-reviewed papers in five years, by its count) lists these studies next to AlphaFold drug repurposing for Chagas disease, AlphaGenome Atlas, AlphaProtein Novo, DeepSomatic and a flu forecast ranked first by the CDC for the 2025–26 season. Google.org says it gave over $60 million in 2026 to groups applying such models to disease. ## Why it matters Interval cancers are the main failure of screening, and the UK lacks radiologists. The result is mostly retrospective: whether an AI reader improves outcomes in live screening is being tested in prospective trials (ICT&health mentions the EDITH trial across 30 sites). The arbitration finding is a warning that humans may overrule correct AI calls. ## What is disputed or not yet verified The Nature Cancer papers were not read directly; titles, author lists and exact publication dates of each paper are not confirmed. The 40% and 32.1% workload figures come from different sources. ## Your AI and this story - GPT-6 Astra (training cutoff April 2026): in its training data - Claude Opus 5.5 (training cutoff June 2026): in its training data - Gemini 3.8 Flash (training cutoff March 2026): in its training data - Grok 4.7 (training cutoff May 2026): in its training data ## Sources 1. [Google: How AI can improve breast cancer detection in the UK (Mar 10, 2026)](https://blog.google/innovation-and-ai/technology/health/google-ai-breast-cancer-detection/) (blog.google, official) 2. [Nature Cancer paper 1 (s43018-026-01127-0)](https://www.nature.com/articles/s43018-026-01127-0) (nature.com, paper) 3. [Nature Cancer paper 2 (s43018-026-01128-z)](https://www.nature.com/articles/s43018-026-01128-z) (nature.com, paper) 4. [Google: Applying technology to understand and treat disease (Oct 12, 2026)](https://blog.google/innovation-and-ai/technology/health/ai-health-research/) (blog.google, official) 5. [ICT&health: AI matches radiologists in breast cancer screening study (Mar 11, 2026)](https://www.icthealth.org/news/ai-matches-radiologists-in-breast-cancer-screening-study) (icthealth.org, press) ## Changes - 2026-10-13 (filed): Created as a review (written from Google's two posts and ICT&health) ## Related - 2026-10-05: [Google DeepMind's AlphaProtein Novo designs new-to-nature enzymes from scratch (piperidine synthesis, DEHP degradation), with Frances Arnold's lab](https://postcutoff.com/e/2026-10-05-deepmind-alphaprotein-novo-enzyme-design/index.md) - 2026-09-08: [AlphaGenome Atlas predicts the effect of all ~9 billion possible single-letter human DNA variants](https://postcutoff.com/e/2026-09-08-alphagenome-atlas/index.md) - People: [Pushmeet Kohli](https://postcutoff.com/person/pushmeet-kohli/)